Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOVA
NCT03689972Phase 3Completed
- Sponsor
- Biogen
- Start
- Nov 2018
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of natalizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Started Nov 2018; status: completed.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT03689972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03689972.